Skip to main content

Table 2 Characteristics of lesions and treatment exposures included in the meta-analysis

From: Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis

Study Group Lesion GLD (μm) (mean ± SD) Interventions Number of Treatments (mean ± SD) (range) Follow up duration (mo) Diagnosis of PCV
Mitamura (2010) PDT 3718 ± 1665 PDT (6 mg/m2) 1PDT 3 Presence of reddish-orange lesions; recurrent serosanguinous RPE detachments; dilated network of inner choroidal vessels with terminal hyperfluorescent aneurysm-like dilatations (polyps) on ICGA.
Anti-VEGF 3651 ± 1833 IVB 1.25 mg 3IVB 3
Rouvas (2011) PDT NA PDT (6 mg/m2) 1.82(1–3)PDT 12 Identification of polyps and interconnecting vessels on the ICGA; presence of subretinal hemorrhages and/or exudation in the macula based on clinical examination
Anti-VEGF NA IVR 0.5 mg 6.9 (3–11)IVR 12
Oishi (2013) PDT 3051.1 ± 1177.7 PDT (6 mg/m2) 1.8PDT 12 PCV was diagnosed based on the presence of polypoidal lesion depicted with ICGA
Anti-VEGF 3347.4 ± 1288.3 IVR 0.5 mg 2.5 IVR 12
Koh (2012) PDT <5400 PDT (6 mg/m2) + sham 1.7(1–4) PDT 6 Presence of early subretinal focal ICGA hyperfluorescence; at least one of the following
clinical criteria: presence of pulsatile polyp; presence of hypofluorescent halo; orange subretinal nodules in fundus photograph
Anti-VEGF <5400 IVR 0.5 mg + sham 5.2 (3–6)IVR 6
Inoue (2013) PDT 3640 ± 2120 PDT (6 mg/m2) 1.52 ± 0.66 PDT 24 presence of clinical, OCT, FA and confocal ICGA findings showing a branching vascular network and polypoidal structures
Anti-VEGF 4171 ± 2631 IVR 0.5 mg 7.1 ± 5.2 IVR 24
Kang (2014) PDT 2810.87 ± 974.10 PDT (6 mg/m2) 2.56 ± 0.38 PDT 24 PCV with subfoveal leakage on FA; presence of branching vascular networks and polypoidal lesions on ICGA
Anti-VEGF 2790.05 ± 871.50 IVR 0.5 mg or IVB 1.25 mg 10.12 ± 1.46 IVR/IVB 24
  1. GLD greatest linear dimension; SD standard deviation; PCV polypoidal choroidal vasculopathy; PDT photodynamic alone; RPE retinal pigment epithelium; VEGF vascular endothelial growth factor; IVB intravitreal bevacizumab; ICGA indocyanine green angiography; NA not available; IVR intravitreal ranibizumab; OCT optical coherence tomography; FA fluorescein angiography